PCRX shorts ease as post-earnings analyst lifts meet a heavily shorted stock

The Street picture is split, and the disagreement is genuine. RBC Capital maintained its cautious Sector Perform rating today while nudging its target a dollar higher to $25 — still below where the stock trades at $27.62. Needham simultaneously lifted its Buy target to $33. That divergence — one analyst flagging fair value below the current price, another pointing 20% higher — captures the bull/bear debate cleanly. Bulls point to the forward earnings trajectory: the 12-month forward earnings growth score ranks in the 97th percentile across the ORTEX universe, and EPS momentum readings at both 30- and 90-day windows are firmly above average. The PE has expanded to roughly 7.9x with EV/EBITDA at 5.7x, both drifting modestly higher over the past month as the stock has appreciated 8.8%. Bears focus on what the ORTEX short score — still elevated at 72.1 despite easing from a recent peak of 73.9 on July 24 — implies about institutional skepticism: the company's EXPAREL franchise faces competition and reimbursement risk, and the EPS surprise factor rank of just 10 suggests the company has been regularly missing analyst expectations in practice even as forward estimates improve.

The short score trajectory is worth watching closely. It peaked around July 24 at 73.9 and has been falling steadily to 72.1 now — a move consistent with the gradual short-position covering evident in the daily SI data. That score decline, combined with the post-earnings analyst lifts today, suggests bearish conviction may be softening at the margin. Insider activity does not add a clear signal in either direction; the 90-day net position across insiders is a modest net sell, with the CFO and Chief Administration Officer both trimming in the $22-$25 range during April and June — a price level now below where the stock trades. Those sales look more like routine plan-driven disposals than conviction calls.

Among the closest correlated peers, AMLX stood out this week with an 11.9% gain and a single-day jump of 8.4%, while INVA and MRK both gave back ground, down around 4% and 3% respectively on the week. PCRX's 3% weekly gain lands it comfortably in the middle of the peer pack — neither a standout performer nor a laggard, which fits the narrative of a stock stabilising rather than breaking out.

With the next earnings event not until October 30, the weeks ahead will be shaped by whether the gap between RBC's cautious $25 target and the $33 Bull case from Needham gets resolved through fundamental newsflow — particularly any update on the PCRX-201 gene therapy pipeline — or whether the 16%-short position continues to gradually unwind as the stock holds above the levels where insiders were selling earlier this year.